Wikisage, the free encyclopedia of the second generation, is digital heritage
Epilepsy: Difference between revisions
(→Links: 2) |
m (→Links) |
||
Line 67: | Line 67: | ||
[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4499082/pdf/IJPH-43-1616.pdf The Efficacy of Leviteracetam versus Carbamazepine for Epilepsy: A Meta-Analysis] | [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4499082/pdf/IJPH-43-1616.pdf The Efficacy of Leviteracetam versus Carbamazepine for Epilepsy: A Meta-Analysis] | ||
[http://onlinelibrary.wiley.com/doi/10.1111/epi.12182/epdf The intrinsic severity hypothesis of pharmacoresistance to antiepileptic drugs] | |||
[[Dravet's syndrome]] | [[Dravet's syndrome]] |
Revision as of 17:53, 29 July 2015
Classification of ethiology could divided in four categories:
- idiopathic epilepsy
- symptomatic epilepsy
- provoked epilepsy
- cryptogenic epilepsy
[1] It is difficult to distinguish between genetic and cryptogenic syndromes.
Morbility data is difficult to interpret when WHO[2] states 50-70 millions persons[3] suffers epilepsy[4]
nonadherence appears to be associated with increased health care costs, nevertheless XR-medicine appears as strategy to overcome compliance wih AED[5]
Medicines | ||||
type | ,,, | ,,,, | ||
INN | Generic | slow release | ||
carbamazepine | normal | xr | ||
lamotrigine | normal | xr | ||
levetiracetam | normal | xr | ||
oxcarbazepine | ... | xr | ||
phenitoin | ... | xr | ||
valproate | xr | |||
topiramate | xr | |||
AED |
ILAE Classification
See also
A new perspective for Epileptic Disorders
Links
Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population
The Efficacy of Leviteracetam versus Carbamazepine for Epilepsy: A Meta-Analysis
The intrinsic severity hypothesis of pharmacoresistance to antiepileptic drugs
References: |
|